Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 17/20 | 0.59 |
| ▸ | FGF1 | P05230 | 9/20 | 0.59 |
| ▸ | FGF2 | P09038 | 8/20 | 0.58 |
| ▸ | POLA1 | P09884 | 1/20 | 0.54 |
| ▸ | CDC25A | P30304 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12590996 | 1.00 | HPSE (0.59) | HPSEFGF1FGF2POLA1CDC25A | |
| SCHEMBL12591000 | 0.90 | HPSE (0.64) | HPSEFGF1FGF2POLA1CDC25A | |
| SCHEMBL2059166 | 0.84 | NR1H4 (0.68) | HPSEFGF1FGF2POLA1CDC25A | |
| SCHEMBL13211407 | 0.84 | NR1H4 (0.68) | HPSEFGF1FGF2POLA1CDC25A | |
| SCHEMBL12590999 | 0.84 | NR1H4 (0.68) | HPSEFGF1FGF2POLA1CDC25A | |
| SCHEMBL2059338 | 0.83 | HPSE (0.54) | HPSEFGF1FGF2CDC25A | |
| SCHEMBL13211410 | 0.82 | HPSE (0.54) | HPSEFGF1FGF2POLA1CDC25A | |
| SCHEMBL11421869 | 0.81 | VDR (0.53) | HPSEFGF1FGF2 | |
| SCHEMBL24403430 | 0.79 | VDR (0.79) | POLA1CDC25A | |
| SCHEMBL13214256 | 0.79 | VDR (0.79) | POLA1CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921086-B1 | ANTITUMOR AGENT | OTSUKA PHARMA CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-7968116-B2 | Antitumor agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20100292176-A1 | ANTITUMOR AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-1921086-A1 | ANTITUMOR AGENT | Otsuka Pharmaceutical Co., Ltd. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292176-A1 | ANTITUMOR AGENT | CYP46A1, CETP, GYS2 | HPSE 1920/4885FGF1 2169/4885FGF2 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.